CJC-1295 DAC or no-DAC: how the two versions differ

Last updated 2026-07-26

What is the actual difference between CJC-1295 with DAC and without DAC?

DAC stands for Drug Affinity Complex, a maleimide-linked side chain that lets the peptide bind covalently to circulating albumin. That binding is the entire story here. Once attached to albumin, the peptide gets protected from enzymatic breakdown and recirculates in the bloodstream for days instead of minutes. CJC-1295 without DAC is really just a modified version of growth hormone releasing hormone (GHRH) 1-29, often labeled mod GRF (1-29) in research catalogs. It has the same core amino acid sequence changes (four substitutions designed to resist enzymatic degradation, described in the original pharmacology paper by Teichman and colleagues) but no albumin-binding tail ^[1]. Without that tail, it behaves close to native GHRH: fast onset, fast clearance. The original human study of CJC-1295 (with DAC) reported a mean elimination half-life of about 6.8 days after a single subcutaneous dose, with sustained elevation of GH and IGF-1 for at least 6 days at higher doses ^[1]. That is the source of essentially every '1-week half-life' claim you see repeated online. No-DAC CJC-1295 has not been through a comparable published pharmacokinetic study under that name; its expected half-life is inferred from native GHRH(1-29) analogue behavior, generally cited in the 30-minute range in secondary and industry literature rather than a dedicated clinical trial. So the core tradeoff is duration versus pulsatility. DAC gives you a long, flat elevation of GH and IGF-1 from one injection. No-DAC gives you a short spike that mimics a single natural GHRH pulse, then disappears.

CJC-1295 with DAC vs no-DAC: side-by-side comparison

Why does the DAC molecule last so much longer in the body?

The mechanism is straightforward biochemistry, not marketing. DAC is a maleimide group that forms a stable covalent bond with the cysteine-34 residue on human serum albumin, one of the most abundant and long-lived proteins in blood ^[1]. Albumin itself has a plasma half-life measured in weeks, so anything bound tightly to it inherits some of that longevity. Without DAC, the peptide is a free molecule circulating on its own. Peptidases and general proteolytic clearance mechanisms degrade unprotected GHRH analogues quickly, which is exactly why native GHRH itself has a half-life of just a few minutes in normal physiology. The four amino acid substitutions in both CJC-1295 versions (versus native GHRH 1-29) slow that degradation somewhat, but they don't come close to matching what albumin-binding does ^[1]. Think of it as the difference between a boat with an engine (DAC, self-sustaining for days) and a boat caught in a current (no-DAC, moving fast but only until the current stops).

Does DAC or no-DAC better match how the body naturally releases GH?

This is where the honest answer disappoints people looking for a clean winner. Natural GH release is pulsatile: the hypothalamus fires GHRH in bursts, mostly during slow-wave sleep, producing sharp GH spikes rather than a flat elevation ^[2]. No-DAC CJC-1295 given as a short-acting bolus, especially before bed, is designed to mimic that pattern more closely on paper. DAC's whole appeal is the opposite of pulsatility: continuous, low-grade GHRH receptor stimulation for days. Some researchers have raised the theoretical concern that constant stimulation could desensitize GHRH receptors on pituitary somatotrophs over time, blunting the pulse the body would otherwise generate on its own. This concern shows up frequently in peptide research discussion but is not something the original human trial was designed or powered to test; the study measured GH and IGF-1 levels over days, not receptor sensitivity over months ^[1]. So neither claim, 'DAC preserves natural rhythm' or 'DAC blunts it long-term,' has a dedicated clinical trial behind it in humans using repeated dosing. What we have is a plausible mechanism-based argument on each side and a single-dose PK study. That's a real gap in the evidence, and anyone telling you it's settled science is overselling it.

Why is CJC-1295 usually paired with ipamorelin instead of used alone?

The rationale is receptor biology, not folklore, even though most of the specific dosing protocols circulating online did originate on bodybuilding forums rather than in journals. CJC-1295 acts on GHRH receptors. Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin/GHS receptor, a separate pathway ^[3]. Stimulating both pathways at once is a well-documented strategy in endocrinology research generally: GHRH analogues and GH secretagogues have been shown in various combination studies (using different specific peptides than this exact pair) to produce a larger GH pulse together than either alone, because they work through non-overlapping mechanisms ^[4]. Ipamorelin in particular was developed and characterized specifically for its selectivity, meaning it doesn't meaningfully raise cortisol, prolactin, or ACTH the way earlier secretagogues like GHRP-6 sometimes do ^[3]. What's folklore versus what's documented: the mechanism-based rationale for combining a GHRH analogue with a ghrelin-receptor agonist is grounded in real receptor pharmacology ^[3][4]. The specific claim that 'CJC-1295 and ipamorelin together' produces a defined, reproducible clinical outcome in humans, at the doses and frequencies typically discussed online, has not been established in a published trial using that exact combination. Nobody has run the definitive human trial on this specific pairing at the doses forum culture recommends. Treat the mechanism as real and the specific dosing protocols as unverified.

Which version, DAC or no-DAC, is typically paired with ipamorelin and why?

In practice, no-DAC CJC-1295 is paired with ipamorelin far more often than the DAC version, and the logic tracks back to pulsatility again. Ipamorelin's own half-life is short, roughly 2 hours based on early pharmacological characterization, and it's typically dosed to align with a GH pulse, often at night ^[3]. Pairing a fast-clearing GHRH analogue (no-DAC CJC-1295) with a fast-clearing secretagogue (ipamorelin) means both drugs are stimulating the pituitary at the same time, producing one coordinated GH pulse before the peptides clear. Pairing DAC's multi-day steady-state elevation with ipamorelin's short pulses is a mismatch in duration profile: you'd have background GHRH stimulation running continuously while ipamorelin pulses land on top of it intermittently. Some protocols still do this deliberately, aiming for a combination of sustained baseline plus periodic peaks, but it's a different strategy than the pulse-matching approach and has even less published human data behind it specifically.

How is CJC-1295 with DAC dosed differently from no-DAC?

Frequency is the main practical difference and it flows directly from half-life. No-DAC CJC-1295's short clearance time means single doses don't accumulate much between injections, so research protocols using it typically involve daily or multiple-times-daily dosing to maintain any meaningful effect. DAC's multi-day half-life means the opposite: dosing it daily would just stack circulating peptide on top of peptide that hasn't cleared yet, which is why protocols using DAC typically space injections out to once or twice weekly. The original clinical PK study used single ascending doses (up to 90 mcg/kg) and found sustained GH and IGF-1 elevation through at least day 6 at the higher dose levels, then measured decline from there ^[1]. That data point is where the 'once or twice a week' framing for DAC comes from; it is not itself a validated repeat-dosing regimen, since the study didn't test repeated administration over weeks or months. Handling matters regardless of which version you're using. Both come as lyophilized powder requiring correct reconstitution and cold storage; mistakes here affect potency more than any half-life difference does. See CJC-1295 reconstitution and CJC-1295 storage and shelf life for the practical steps, and CJC-1295 injection sites for site rotation guidance that applies to both forms.

Is one version, DAC or no-DAC, safer than the other?

There isn't a published head-to-head human safety trial comparing the two directly, so any confident safety ranking you read is going beyond the data. What we do have: the DAC study reported the compound was generally well tolerated at the doses tested, with injection site reactions being the most commonly noted adverse event in that small cohort ^[1]. The broader safety concern that applies to both versions, and to GH secretagogues generally, is that sustained elevation of GH and IGF-1 raises theoretical concerns around insulin sensitivity and, over long time periods, cell growth signaling. These concerns are part of why GH and GHRH analogues remain prescription-regulated substances rather than over-the-counter supplements in the United States, and why compounded or research-labeled versions fall outside standard FDA oversight ^[5]. Neither CJC-1295 variant is FDA-approved for any human indication, and neither has long-term safety data in healthy adults using these substances outside of a clinical trial setting ^[5]. For a fuller breakdown of documented risks, monitoring considerations, and what the regulatory status actually means for buyers, read is CJC-1295 safe.

What does the evidence actually say versus what is bodybuilding forum lore?

This distinction matters more for CJC-1295 than for almost any other peptide people ask about, because so much of the popular material genuinely does originate in forum culture rather than in journals. What's documented: the amino acid sequence and its four substitutions versus native GHRH ^[1]. The DAC albumin-binding mechanism and its single-dose human PK data, including the ~6.8 day half-life figure ^[1]. GH and IGF-1 elevation in that same small trial ^[1]. Ipamorelin's receptor selectivity and short half-life from its own pharmacological characterization ^[3]. The general endocrine principle that pulsatile GH release during sleep is how the body normally does it ^[2]. What's forum-derived and unverified: specific microgram dosing charts for either version, claimed 'ideal' injection timing windows down to the hour, claims about fat-loss or muscle-gain outcomes attributed to this specific peptide combination at these specific doses, and any claim that DAC 'burns out' GHRH receptors based on real human trial data (that concern is mechanistically plausible but untested at this level of specificity). If a source states a precise dosing protocol with total confidence and no citation, that protocol almost certainly traces back to forum consensus, not a clinical study.

Does cost or availability differ between DAC and no-DAC CJC-1295?

Per-vial pricing in the research chemical supply market varies more by seller and purity testing practices than by DAC status specifically, but DAC's larger, more complex molecule (the added maleimide linker) generally makes it somewhat more expensive to synthesize than the shorter no-DAC peptide, which sometimes shows up as a modest price premium. Availability-wise, both versions are widely sold as 'research use only' products, a labeling distinction that exists because neither is FDA-approved for human use; that label is a real regulatory marker, not a marketing footnote ^[5]. Buyers comparing sources should weight third-party purity testing and provider transparency far more heavily than a small price difference between DAC and no-DAC vials. For a rundown of what to look for and where inventory tends to be more consistently verified, see CJC-1295 for sale and how to get CJC-1295.

How do you choose between DAC and no-DAC for a given use case?

Reduce it to one honest question: are you optimizing for convenience or for pulsatility. If the goal is fewer injections and a steady, sustained GH/IGF-1 elevation, DAC's pharmacokinetic profile is built for that, once or twice weekly dosing based on the single-dose trial data available ^[1]. If the goal is mimicking a natural GH pulse, particularly one timed around sleep and stacked with a secretagogue like ipamorelin, no-DAC's fast clearance is the mechanistically coherent choice, even though the specific combined-dosing outcome hasn't been validated in a dedicated trial ^[3][4]. Neither choice is validated for any specific outcome (fat loss, muscle gain, anti-aging effects) in a published human efficacy trial. What's published is pharmacokinetics and short-term GH/IGF-1 response, not downstream body composition or performance results ^[1]. Anyone promising a specific physique outcome from either version is extrapolating well past what the data shows. CJC-1295 Co's position on this: the DAC-vs-no-DAC decision should be made with a provider who can review your goals and health history, not by copying a forum protocol. Sourcing matters as much as the molecule choice; work through a provider-reviewed route with a named, verifiable fulfilling pharmacy rather than an anonymous research chemical vendor.

What questions should you ask before starting either version?

Ask what the injection frequency will actually look like week to week, since that's the most concrete real-world difference between the two forms. Ask what monitoring, if any, is planned for IGF-1 levels, since that's the one lab marker the original human trial actually tracked as a response measure ^[1]. Ask whether the specific product has any third-party purity or identity testing behind it, since 'research use only' labeling means there's no FDA batch oversight to fall back on ^[5]. And ask, honestly, whether the person or source recommending a specific protocol can point to a study, or whether the protocol is forum consensus dressed up as certainty. That single question filters out most of the bad advice circulating around this peptide.

Frequently asked questions

What does DAC stand for in CJC-1295 DAC?

DAC stands for Drug Affinity Complex. It's a maleimide linker attached to the peptide that lets it bind covalently to serum albumin in the blood, protecting it from rapid enzymatic breakdown. That binding is why CJC-1295 with DAC has a reported half-life of roughly 6.8 days versus about 30 minutes for the no-DAC version ^[1].

Is no-DAC CJC-1295 the same thing as mod GRF 1-29?

Yes, in common usage. 'No-DAC CJC-1295' and 'mod GRF (1-29)' both refer to the same modified GHRH(1-29) analogue without the albumin-binding tail. The naming is inconsistent across sellers, which is a real source of confusion, so check the actual peptide sequence a supplier lists rather than relying on the label alone.

Which lasts longer in the body, CJC-1295 with DAC or without?

CJC-1295 with DAC lasts much longer. A single-dose human pharmacokinetic study reported a mean elimination half-life of about 6.8 days, with GH and IGF-1 still elevated at day 6 in higher-dose groups ^[1]. No-DAC CJC-1295 clears in roughly 30 minutes based on its similarity to native GHRH(1-29) behavior, though no dedicated PK trial has published that figure directly.

Can you combine CJC-1295 DAC with ipamorelin, or does it have to be no-DAC?

Some protocols do combine DAC with ipamorelin, aiming for a sustained baseline plus periodic pulses, but no-DAC is the more common pairing because its short half-life better matches ipamorelin's own roughly 2-hour clearance, producing one coordinated pulse rather than a mismatch of durations. Neither specific combination has a dedicated human efficacy trial behind it.

Does CJC-1295 with DAC desensitize GHRH receptors over time?

This is a real theoretical concern raised in peptide research discussion: continuous GHRH receptor stimulation could plausibly blunt receptor sensitivity over months of use. It has not been tested in a published human trial with repeated DAC dosing, since the original study used single doses only ^[1]. Treat this as an open question, not a settled finding either way.

Is CJC-1295 (either version) FDA-approved?

No. Neither CJC-1295 with DAC nor without DAC is approved by the FDA for any human indication. Both are typically sold labeled 'research use only,' a regulatory distinction that means there's no FDA oversight of manufacturing, purity, or dosing for products sold this way ^[6].

Why is CJC-1295 usually stacked with ipamorelin instead of another GH peptide?

CJC-1295 stimulates GHRH receptors while ipamorelin stimulates the separate ghrelin/GHS receptor pathway, and ipamorelin was specifically developed for high receptor selectivity, meaning minimal cortisol or prolactin spillover compared to older secretagogues like GHRP-6 ^[4]. Combining non-overlapping GH-stimulating pathways is a documented pharmacological strategy, though this exact pairing lacks its own dedicated human trial ^[4][5].

How often do you inject CJC-1295 with DAC versus without DAC?

DAC's multi-day half-life supports once or twice weekly injections in most research protocols, based on the sustained elevation seen through day 6 in the original PK study ^[1]. No-DAC's roughly 30-minute clearance means it's typically dosed daily, or even multiple times a day, to produce repeated GH pulses.

Does either version of CJC-1295 have documented side effects?

The single-dose human trial of CJC-1295 with DAC reported the compound was generally well tolerated, with injection site reactions as the most commonly noted issue ^[1]. Broader theoretical concerns around sustained GH/IGF-1 elevation, including effects on insulin sensitivity, apply to GH secretagogues generally rather than being specific to one CJC-1295 version ^[6].

Is DAC or no-DAC CJC-1295 better for fat loss or muscle gain?

Neither has a published human trial demonstrating fat loss or muscle gain outcomes at any specific dose. The available human data covers pharmacokinetics and short-term GH/IGF-1 response only ^[1]. Any body composition claim attached to either version is extrapolation from GH's general physiological role, not a direct trial finding for this peptide.

What's the difference in cost between CJC-1295 DAC and no-DAC?

Pricing varies more by seller and purity testing than by DAC status, but DAC's larger, more complex molecular structure generally costs somewhat more to synthesize, which sometimes shows up as a modest per-vial premium over no-DAC product. Purity verification matters far more to overall value than that price gap.

Where does most CJC-1295 dosing advice online actually come from?

Much of the specific microgram dosing, timing, and stacking advice circulating for CJC-1295 originates in bodybuilding forum culture rather than published clinical research. The core molecular pharmacology, sequence, DAC mechanism, and single-dose PK data are documented in a peer-reviewed source ^[1], but repeat-dosing protocols and outcome claims generally are not.

Sources

1. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting growth-hormone-releasing hormone analog" (PMID 16352683): CJC-1295 with DAC mean elimination half-life ~6.8 days, sustained GH/IGF-1 elevation through day 6, tolerability data, four amino acid substitutions vs native GHRH
2. U.S. Food and Drug Administration, Federal Register, "Compounded Drugs; Bulk Drug Substances Used in Compounding" (list determinations for section 503A): GHRH analogues including CJC-1295 have been evaluated by FDA under bulk drug substance nomination processes and are not approved for compounding into human drug products
3. StatPearls (NCBI Bookshelf), "Physiology, Growth Hormone", PMID 30521262: Natural growth hormone release occurs in pulsatile bursts linked to sleep, not continuous elevation
4. Raun K et al., European Journal of Endocrinology, "Ipamorelin, the first selective growth hormone secretagogue", PMID 9820189: Ipamorelin receptor selectivity, minimal cortisol/ACTH/prolactin release compared to other secretagogues, short half-life
5. Bowers CY, "Growth hormone-releasing peptide (GHRP)", Cellular and Molecular Life Sciences, PMID 9539787: Combining GHRH analogues with ghrelin-receptor secretagogues can produce additive GH pulse amplitude via non-overlapping receptor pathways
6. U.S. Food and Drug Administration, "Compounding and the FDA: Questions and Answers": Peptides labeled research use only lack FDA approval and oversight for human dosing, purity, or manufacturing